Core Viewpoint - Dongyangguang Pharmaceutical is advancing its AI strategy by launching an AI-driven research and development platform focused on the PROTAC mechanism, aiming to provide a comprehensive data foundation for rational design and clinical translation of PROTAC lead compounds [1][2]. Group 1: AI Strategy and Platform Development - The company is building a high-quality, structured PROTAC-specific database (HEC PROTAC DB) that integrates molecular structures, degradation activity, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2]. - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2]. - An AI molecular generation and screening platform has been developed based on this database, creating a "data-generation-computational validation-experimental feedback" closed loop to accelerate the rational design and clinical translation of PROTAC lead compounds [2]. Group 2: Collaboration and Drug Development - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing Deep Technology Co., Ltd. and Huawei Cloud Computing Technology Co., Ltd., establishing six proprietary models covering the entire drug discovery process [3]. - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 – 1 – SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 推出全球領先的PROTAC機制AI智能研發平台 本 公 告 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）自願刊發。 本集團持續深化AI戰略佈局，推出面向PROTAC機制的AI智能研發平台，實現從 數據底座到「乾濕閉環」，數據規模與結構粒度均顯著領先於現有公開數據庫，為 AI 驅 動的 PROTAC 理 性設 計 提供 了 全面 、 系 統的 數 據基 礎 ，加 速 PROTAC 先導 化 合物的理性設計與臨床轉化。 研發背景：破解「不可成藥」困局，PR ...